Zhitong Financial App News, and Platinum Pharmaceutical-B (02142) announced that China's National Drug Administration (NMPA) has approved the marketing of bartolizumab injection (subcutaneous injection) (bartholizumab subcutaneous injection) (170 mg (1 mL)/bottle) to be used in combination with conventional drugs to treat adult systemic myasthenia gravis (GmG) patients with positive anti-acetylcholine receptor (AChR) antibodies. Bartolizumab (HBM9161) is the company's core product under Chapter 18A of the Listing Rules. Bartolizumab subcutaneous injection is the Group's first approved product. It is also the first anti-neonatal Fc receptor (FcRn) therapy to complete clinical development for GMG patients in China.

According to the licensing agreement signed between the Group and Enbipu Pharmaceutical, a subsidiary of CSPC Group, in October 2022, the commercialization of bartolizumab in Greater China (including mainland China, Hong Kong, Macau and Taiwan) is responsible for the commercialization of bartolizumab in the Greater China region (including mainland China, Hong Kong, Macau and Taiwan). The Group is entitled to receive tiered royalties based on the annual net sales of bartolizumab in Greater China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.